Pharma Two B
  • Home
  • Our Company
    • Who We Are
    • Pharma Two B Team
    • Board of Directors
  • Our Focus
    • Our Development Approach
    • Our Regulatory Approach
    • Intellectual Property
    • Strategic Partnerships
  • Patients & Families
    • Parkinson’s disease
    • Resources
  • Our Pipeline
    • P2B001
    • Clinical Trials
    • Pipeline and Future Products
    • Possible Risk Related to P2B001 Clinical Trials
    • Drug-drug combinations
  • News & Events
    • Press Releases
    • Events
    • Publications
  • Contact Us
  • Home
  • Our Company
    • Who We Are
    • Pharma Two B Team
    • Board of Directors
  • Our Focus
    • Our Development Approach
    • Our Regulatory Approach
    • Intellectual Property
    • Strategic Partnerships
  • Patients & Families
    • Parkinson’s disease
    • Resources
  • Our Pipeline
    • P2B001
    • Clinical Trials
    • Pipeline and Future Products
    • Possible Risk Related to P2B001 Clinical Trials
    • Drug-drug combinations
  • News & Events
    • Press Releases
    • Events
    • Publications
  • Contact Us
Pharma Two B
  • Home
  • Our Company
    • Who We Are
    • Pharma Two B Team
    • Board of Directors
  • Our Focus
    • Our Development Approach
    • Our Regulatory Approach
    • Intellectual Property
    • Strategic Partnerships
  • Patients & Families
    • Parkinson’s disease
    • Resources
  • Our Pipeline
    • P2B001
    • Clinical Trials
    • Pipeline and Future Products
    • Possible Risk Related to P2B001 Clinical Trials
    • Drug-drug combinations
  • News & Events
    • Press Releases
    • Events
    • Publications
  • Contact Us
  • Home
  • Our Company
    • Who We Are
    • Pharma Two B Team
    • Board of Directors
  • Our Focus
    • Our Development Approach
    • Our Regulatory Approach
    • Intellectual Property
    • Strategic Partnerships
  • Patients & Families
    • Parkinson’s disease
    • Resources
  • Our Pipeline
    • P2B001
    • Clinical Trials
    • Pipeline and Future Products
    • Possible Risk Related to P2B001 Clinical Trials
    • Drug-drug combinations
  • News & Events
    • Press Releases
    • Events
    • Publications
  • Contact Us
Pharma Two B taking ‘synergistic’ approach in pursuit of 505(b)(2) approval
Home » Press Release » Pharma Two B taking ‘synergistic’ approach in pursuit of 505(b)(2) approval

Pharma Two B taking ‘synergistic’ approach in pursuit of 505(b)(2) approval

http://bit.ly/gS5LF5

Next »
Pharma Two B
Pharma Two B Ltd. 3 Pekeris Street, Weizmann Science Park, Rehovot, 7670203 Israel
Tel: +972-8-9472672 , Fax: +972-8-9366832
Privacy Policy    Terms of Use    PharmaTwoB. All rights reserved © 2017
Scroll to top